{"product_id":"inotivco-business-model-canvas","title":"Inotiv Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas for Preclinical Research Services: Value, Scale, Monetization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint of Inotiv with our Business Model Canvas—three to five concise sections revealing how it creates value, scales services, and monetizes scientific research. This professional, editable canvas is perfect for investors, consultants, and founders. Download the complete Word and Excel files for immediate benchmarking and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and biotech sponsors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with pharmaceutical and biotechnology sponsors drive a steady pipeline of discovery-to-IND programs, and in 2024 these partnerships continue to supply study demand, test compounds, and therapeutic direction. Co-designing protocols with sponsors aligns risk, timelines, and regulatory expectations. Multi-year MSAs stabilize utilization and capacity planning for predictable lab throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and research institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUniversities and research institutes furnish cutting-edge disease biology, validated models and early targets, feeding Inotiv pipelines with discoveries drawn from a research ecosystem producing roughly 3 million peer-reviewed articles annually. Joint studies and sponsored research—supported by major funders like NIH (~49 billion USD FY2024)—expand scientific depth and third-party credibility. Access to graduate talent, high-impact publications and consortia elevates company visibility and deal flow. Technology transfer agreements can seed new service lines and licensing revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModel suppliers and breeding genetics partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlliances with breeders and genetics firms secure compliant animal supply and, in 2024, support a preclinical animal model market exceeding $4 billion, ensuring study capacity and regulatory traceability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and standards bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngagement with FDA, EMA, OECD (38 members in 2024) and AAALAC aligns Inotiv practices with current expectations; early scientific advice from regulators smooths study design and endpoints, reducing downstream protocol amendments and timeline risk. Active participation in working groups informs upcoming guidance, while certifications and accreditations (AAALAC: \u0026gt;1,200 accredited programs worldwide in 2024) reinforce sponsor confidence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory alignment: FDA, EMA, OECD (38 members)\u003c\/li\u003e\n\u003cli\u003eEarly advice: fewer protocol amendments\u003c\/li\u003e\n\u003cli\u003eWorking groups: input into upcoming guidance\u003c\/li\u003e\n\u003cli\u003eAccreditations: AAALAC \u0026gt;1,200 programs (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and platform vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with LC\/MS, imaging, telemetry, LIMS and bioinformatics vendors boosted throughput and data quality for Inotiv, yielding estimated throughput gains of 20–30% and enabling 2024 SLAs of ~99.5% uptime; co‑validation of methods cut assay readiness timelines significantly, while preferred pricing and service SLAs reduced instrument downtime and operating costs. Integration support streamlined secure, near real‑time data delivery to clients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThroughput +20–30%\u003c\/li\u003e\n\u003cli\u003eSLA uptime ~99.5% (2024)\u003c\/li\u003e\n\u003cli\u003eFaster assay readiness via co‑validation\u003c\/li\u003e\n\u003cli\u003ePreferred pricing reduces OPEX\u003c\/li\u003e\n\u003cli\u003eIntegrated data delivery, near real‑time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscovery-to-IND deals surge: NIH \u003cstrong\u003e$49B\u003c\/strong\u003e, preclinical \u0026gt; \u003cstrong\u003e$4B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with pharma\/biotech and universities supply discovery-to-IND programs, validated models and talent; NIH funding ~$49B (FY2024) boosts academic deal flow. Breeders\/genetics secure animal supply in a \u0026gt;$4B preclinical model market (2024). Regulators and AAALAC (\u0026gt;1,200 programs, 2024) reduce timeline risk. Vendor alliances drove +20–30% throughput and ~99.5% SLA uptime (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH\u003c\/td\u003e\n\u003ctd\u003e$49B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAAALAC\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,200 programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVendors\u003c\/td\u003e\n\u003ctd\u003e+20–30% throughput; 99.5% SLA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Inotiv that maps its 9 BMC blocks with detailed value propositions, customer segments, channels and revenue streams, includes SWOT and competitive-advantage analysis, and is tailored for investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Inotiv’s strategy into a one-page, editable Business Model Canvas that saves hours of formatting and clarifies core components for quick review. Perfect for team collaboration, boardroom presentations, and fast comparisons across companies or scenarios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNonclinical pharmacology and toxicology studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning and executing GLP and non-GLP efficacy and safety studies is core to Inotiv’s services, with dose-range finding, repeat-dose tox and safety pharmacology underpinning IND-enabling packages. Species selection and tailored endpoints match mechanism of action, while rigorous controls and AAALAC-accredited practices (over 1,100 programs worldwide in 2024) ensure reproducibility and compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDMPK and bioanalysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDMPK and bioanalysis perform ADME and PK\/PD profiling to inform candidate selection and metabolite ID, addressing the \u0026gt;90% clinical attrition driven by poor pharmacokinetics. Validated LC\/MS methods enable sensitive, matrix-spanning quantitation for plasma, tissue, and CSF. Integrated in vitro and in vivo studies characterize exposure, clearance, and interaction risks, feeding data into modeling for dose and study design.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch models and related product provision\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResearch models: Inotiv (NASDAQ: NOTV) breeds, maintains and supplies disease and safety models that underpin preclinical studies, with health monitoring and genetics validation to ensure model integrity. Customized cohorts are produced to match sponsor protocols and timelines. Ancillary products and services streamline study start-up and logistics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory support and submissions enablement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory support delivers study reports, summaries and CTD-ready documentation to enable IND\/CTA filings, while gap assessments pinpoint additional nonclinical or CMC work needed. Sponsor consultations align endpoints and statistical plans with agency guidance to reduce review cycles. Audit readiness and coordinated responses ensure inspection compliance and timely issue resolution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCTD-ready documentation\u003c\/li\u003e\n\u003cli\u003eGap assessments\u003c\/li\u003e\n\u003cli\u003eSponsor consultations\u003c\/li\u003e\n\u003cli\u003eAudit readiness \u0026amp; responses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality assurance and compliance management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGLP systems, rigorous SOPs and routine audits ensure regulatory-grade nonclinical outputs, aligned with 21 CFR Part 58 and ALCOA+ data integrity principles in 2024. Continuous training, robust deviation handling and CAPAs sustain quality and reduce repeat findings. Secure data integrity and archival protect sponsor IP and enable inspection readiness through continuous improvement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGLP (21 CFR Part 58)\u003c\/li\u003e\n\u003cli\u003eSOPs \u0026amp; audits\u003c\/li\u003e\n\u003cli\u003eTraining, deviations, CAPA\u003c\/li\u003e\n\u003cli\u003eData integrity \u0026amp; archival\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP\/non‑GLP studies DMPK \u0026amp; validated models cut clinical attrition by \u003cstrong\u003e\u0026gt;90%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInotiv (NASDAQ: NOTV) conducts GLP\/non‑GLP efficacy and safety studies—over 1,100 programs worldwide in 2024—and DMPK\/bioanalysis for ADME\/PKPD to mitigate \u0026gt;90% clinical attrition risks. It breeds and supplies validated disease\/safety models and custom cohorts. It provides CTD-ready regulatory support, gap assessments and audit‑ready GLP systems (21 CFR Part 58, ALCOA+).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP\/non‑GLP studies\u003c\/td\u003e\n\u003ctd\u003e1,100+ programs\u003c\/td\u003e\n\u003ctd\u003eIND‑enabling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMPK \u0026amp; bioanalysis\u003c\/td\u003e\n\u003ctd\u003eValidated LC\/MS assays\u003c\/td\u003e\n\u003ctd\u003ePK\/PD, metabolite ID\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModels \u0026amp; cohorts\u003c\/td\u003e\n\u003ctd\u003eBreeding \u0026amp; supply\u003c\/td\u003e\n\u003ctd\u003eGenetics \u0026amp; health monitoring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Inotiv Business Model Canvas you'll receive—it's not a mockup or sample. After purchase you'll instantly download this same complete, editable file with all content and pages included. It's ready to edit, present, and apply with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162234139001,"sku":"inotivco-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/inotivco-business-model-canvas.png?v=1762697725","url":"https:\/\/portersfiveforce.com\/products\/inotivco-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}